MARKET WIREYahoo Finance • 21h ago
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar TodayYahoo Finance report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
Why LPCN Stock advanced +0.69% Today — RQD Quant Desk Flash
$1.45 +0.69% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.45
Lipocine Inc. (LPCN) carries a Roarable Rating of E (Strong Sell) with 23/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $11.9M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LPCN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LPCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Lipocine Inc. (NASDAQ: LPCN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $1.45 (+0.69% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LPCN ranks #954 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LPCN compare to RKTO and KTTA in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LPCN carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RKTO (Rocket One Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.1M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M). Among the 5-stock peer group, LPCN leads on earnings multiple (N/A) while LPCN leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LPCN?
▼
Per LPCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001535955), Lipocine Inc. generated $2.0M in revenue (-82.3% YoY), -$9.6M in net income, and -$9.8M in free cash flow against $17.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.45 (-0.07%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (23/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-15.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LPCN)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (23/100 Composite)
🔍 WHY LPCN SCORES 23/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+7/20 pts (30% of score)
FRED Regime × Technicals: 2% of 52W Range • RSI-14 at 34.1 (NEUTRAL RANGE)
▲ #2 Bullish Driver: Cash Engine Quality+5/20 pts (22% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.62+0% Next Q
31
Q2 (-2Q)Grade E$1.62-9.9% Next Q
28
Q3 (-1Q)Grade E$1.46-0.7% Next Q
26
CurrentGrade E$1.45-11.1% Hist 90D α
23
Trajectory: E (31) → E (23)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LPCN Turnaround Squeeze
While LPCN currently carries a cautious 23/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.96) and Max Pain ($1.52) forces dealer call-delta covering toward $12.99.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LPCN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LPCN Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LPCN Stock advanced +0.69% Today — RQD Quant Desk Flash
Lipocine Inc. (LPCN) advanced +0.69% to $1.45, trading at 2% of its 52-week range ($1.4 – $12.37). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.4 – $12.37) with RSI-14 at 34.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.45 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LPCN Headlines & Catalysts
MARKET WIRETradingView • 1d ago
Here's Why You Should Add LPCN Stock to Your Portfolio NowTradingView report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStockInvest.us • 1d ago
Lipocine Stock Price Forecast. Should You Buy LPCN?StockInvest.us report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Canada approves a testosterone pill for men, with launch planned by year-end.Stock Titan report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETimothy Sykes • 1d ago
LPCN Stock Pops As BLOOM Phase 3 Trial Kicks OffTimothy Sykes report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
CATALYSTYahoo Finance • 1d ago
Lipocine stock surges 30% on Health Canada drug approvalYahoo Finance report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
CATALYSTQuiver Quantitative • 1d ago
Lipocine Surges After Canada Approves TLANDO | LPCN Stock NewsQuiver Quantitative report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LPCN)
- ✓Walkthrough of LPCN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LPCN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.68%📐 HORIZONTAL RANGE
2026-11-03O $1.52H $1.52L $1.44C $1.45VOL 112.1K
RES: $3.27SUP: $1.25SMA50: $1.96SMA200: $3.82
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LPCN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -82.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on LPCN today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LPCN. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LPCN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LPCN)
Health Care Rank #954 of 1015
⚔️ RKTO vs LPCN Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LPCN vs. RKTO, KTTA, CLRB, ASBP)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Lipocine Inc. (LPCN) ranks #954 by composite RQD confidence (23/100, grade E) and #877 by equity capitalization ($11.9M). Within this direct 5-issuer industry benchmark cohort, LPCN leads on earnings valuation at N/A trailing P/E, while LPCN leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. RKTO currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with LPCN at 23/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LPCN
ACTIVE
Lipocine Inc. | E | 23/100 | — | — | -35.0% | +0.69% | $11.9M | Benchmark Subject |
| RKTO Rocket One Inc. | D- | 40/100 | — | — | -35.0% | -7.68% | $12.1M | /rkto-vs-lpcn → |
| KTTA Pasithea Therapeutics Corp. | D- | 40/100 | — | — | -35.0% | -0.59% | $12.4M | /ktta-vs-lpcn → |
| CLRB Cellectar Biosciences Inc. | E | 32/100 | — | — | -35.0% | +1.25% | $11.4M | /clrb-vs-lpcn → |
| ASBP Aspire-Lakewood Holdings Inc. | D- | 40/100 | — | -1.9% | -35.0% | -9.99% | $11.4M | /asbp-vs-lpcn → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001535955 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lipocine Inc. (LPCN) reported GAAP revenue of $2.0M (-82.3% vs. FY2024 revenue of $11.2M , and +169.3% cumulative change since FY2023) , GAAP net income of -$9.6M, operating cash flow of -$9.8M, and free cash flow of -$9.8M (-644.3% YoY). On the balance sheet, LPCN closed FY2025 with $17.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $2.0M | -$9.6M | -$9.8M | -$9.8M | $17.0M | — |
| FY2024 (FY) | 2024-12-31 | $11.2M | $10.0K | -$1.2M | -$1.3M | $22.5M | — |
| FY2023 (FY) | 2023-12-31 | -$2.9M | -$16.4M | -$11.9M | -$11.9M | — | — |
3. LPCN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LPCN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Lipocine Inc. (NASDAQ: LPCN) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 23/100 at a spot price of $1.45 (+0.69% 1D, market cap $11.9M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 5/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LPCN ranks #954 in composite RQD confidence.
How does LPCN compare to RKTO and KTTA in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LPCN carries a Roarable E (23/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, RKTO (Rocket One Inc.) holds a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.1M) and KTTA (Pasithea Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC -35.0%, cap $12.4M). Among the 5-stock peer group, LPCN leads on earnings multiple (N/A) while LPCN leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LPCN?
Per LPCN's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001535955), Lipocine Inc. generated $2.0M in revenue (-82.3% YoY), -$9.6M in net income, and -$9.8M in free cash flow against $17.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LPCN trading relative to its 50-day, 200-day, and 52-week technical levels?
LPCN last traded at $1.45 (+0.69% on volume of 248,050 shares), positioning the stock -26.02% below its 50-day simple moving average ($1.96) and -62.04% below its 200-day simple moving average ($3.82). Across its 52-week range of $1.40 to $12.37, LPCN sits at the 0.5% percentile with a 14-day RSI of 34.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.27 to $1.63).
ROARABLE RATING BRIEF • RQD 23/100 (E)
✓ SEC XBRL & RQD VERIFIED
LPCN — Lipocine Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Lipocine Inc. (LPCN) earns a live Roarable RQD composite score of 23/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.45 (+0.69% 1D, market capitalization $11.9M).
- Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (5/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Lipocine Inc. (LPCN) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. It is an issuer in this industry with a market capitalization stated as $0.0B.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lipocine Inc. (LPCN) reported $2.0M in annual revenue (up from $11.2M in FY2024, -82.3% YoY) and -$9.6M in GAAP net income. Operating cash flow reached -$9.8M and free cash flow totaled -$9.8M, backed by $17.0M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 23/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.40 – $12.37 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
Upstream and downstream dependencies, sector correlations, and 2nd-order bottlenecks are — The investor should note that the Canadian approval and BLOOM trial, if they materialize as commercial or development milestones, would be the primary channels through which external events could affect the company, but the source does not quantify these links.
- Key Question #1: Can LPCN sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $2.0M and free cash flow of -$9.8M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is LPCN's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
LPCN Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Lipocine Inc. (LPCN) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 21h ago
LPCN Stock Is Surging: Here’s Why Lipocine Is On Traders’ Radar Today Yahoo Finance report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
Here's Why You Should Add LPCN Stock to Your Portfolio Now TradingView report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE StockInvest.us • 1d ago
Lipocine Stock Price Forecast. Should You Buy LPCN? StockInvest.us report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Canada approves a testosterone pill for men, with launch planned by year-end. Stock Titan report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Timothy Sykes • 1d ago
LPCN Stock Pops As BLOOM Phase 3 Trial Kicks Off Timothy Sykes report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Yahoo Finance • 1d ago
Lipocine stock surges 30% on Health Canada drug approval Yahoo Finance report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST Quiver Quantitative • 1d ago
Lipocine Surges After Canada Approves TLANDO | LPCN Stock News Quiver Quantitative report covering Lipocine Inc. (LPCN) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
LPCN Bull vs. Bear Conversation Board — What's Your Call at $1.45?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LPCN 🐻 33% BEARISH CONVICTION
DE DeepValue_CFA RQD DEBATE OPENER • Institutional Buy-Side 🐂 BULLISH
🎯 Target: $1.68 (+16.7%)
📌 Pinned Debate LPCN (E • RQD 23/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $1.44
The street is overcomplicating Lipocine Inc. (LPCN). LPCN (E • RQD 23/100) operating leverage in Biotechnology: Pharmaceutical Preparations is mispriced at $1.44. With an RQD score of 23/100 (E) and Forensic Balance Sheet at 5/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.56.
ArenaChamp_24 🐂 BULL
@DeepValue_CFA Agree on the RQD 23/100 quality, though with 1.0 beta I'm scaling in with half-size at $1.44 and keeping dry powder in case we test $1.34.
FA FadeTheHype RQD DEBATE OPENER • Contrarian Tape Reader 🐻 BEARISH
🎯 Target: $1.20 (-16.7%)
Spot @ $1.44 Revenue fell from $11.2M to $2.0M while FCF was -$9.8M and ROIC was -35%, with a Piotroski F-Score of 1 out of 9.
Careful chasing LPCN at $1.44. Revenue fell from $11.2M to $2.0M while FCF was -$9.8M and ROIC was -35%, with a Piotroski F-Score of 1 out of 9.. Gross margin is 0.0%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.20 on multiple compression.